1. 2011. Abstracts from AIDS vaccine 2011 Bangkok, Thailand 12-15 september, 2011. AIDS Res Hum Retroviruses 27:A1-A148.
2. 2009. Abstracts of AIDS Vaccine 2009. Paris, France. October 19-22, 2009. Retrovirology 6 Suppl 3:O1-52, P1-425.
3. 2010. European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy. Euro Surveill 15.
4. 2003. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen. Drugs R D 4:249-53.
5. Abdool Karim, Q., S. S. Abdool Karim, J. A. Frohlich, A. C. Grobler, C. Baxter, L. E. Mansoor, A. B. Kharsany, S. Sibeko, K. P. Mlisana, Z. Omar, T. N. Gengiah, S. Maarschalk, N.
Arulappan, M. Mlotshwa, L. Morris, and D. Taylor. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Science 329:1168-74.
6. Abdulhaqq, S. A., and D. B. Weiner. 2008. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 42:219-32.
7. Ahlen, G., E. Derk, M. Weiland, J. Jiao, N. Rahbin, S. Aleman, D. L. Peterson, K. Pokrovskaja, D. Grander, L. Frelin, and M. Sallberg. 2009. Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes. Gut 58:560-9.
8. Almeida, J. R., D. A. Price, L. Papagno, Z. A. Arkoub, D. Sauce, E. Bornstein, T. E. Asher, A.
Samri, A. Schnuriger, I. Theodorou, D. Costagliola, C. Rouzioux, H. Agut, A. G. Marcelin, D.
Douek, B. Autran, and V. Appay. 2007. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204:2473-85.
9. Alpert, M. D., A. R. Rahmberg, W. Neidermyer, S. K. Ng, A. Carville, J. V. Camp, R. L. Wilson, M. Piatak, Jr., K. G. Mansfield, W. Li, C. J. Miller, J. D. Lifson, P. A. Kozlowski, and D. T.
Evans. 2010. Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge. J Virol 84:10748-64.
10. Altfeld, M., M. M. Addo, E. S. Rosenberg, F. M. Hecht, P. K. Lee, M. Vogel, X. G. Yu, R.
Draenert, M. N. Johnston, D. Strick, T. M. Allen, M. E. Feeney, J. O. Kahn, R. P. Sekaly, J. A.
Levy, J. K. Rockstroh, P. J. Goulder, and B. D. Walker. 2003. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17:2581-91.
11. Andre, S., B. Seed, J. Eberle, W. Schraut, A. Bultmann, and J. Haas. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72:1497-503.
12. Arthos, J., C. Cicala, E. Martinelli, K. Macleod, D. Van Ryk, D. Wei, Z. Xiao, T. D. Veenstra, T.
P. Conrad, R. A. Lempicki, S. McLaughlin, M. Pascuccio, R. Gopaul, J. McNally, C. C. Cruz, N.
Censoplano, E. Chung, K. N. Reitano, S. Kottilil, D. J. Goode, and A. S. Fauci. 2008. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9:301-9.
13. Awasthi, A., and V. K. Kuchroo. 2009. Th17 cells: from precursors to players in inflammation and infection. Int Immunol 21:489-98.
14. Babiuk, S., M. Baca-Estrada, L. A. Babiuk, C. Ewen, and M. Foldvari. 2000. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 66:199-214.
15. Babiuk, S., M. E. Baca-Estrada, M. Foldvari, L. Baizer, R. Stout, M. Storms, D. Rabussay, G.
Widera, and L. Babiuk. 2003. Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin. Mol Ther 8:992-8.
41
16. Bailey, J. 2008. An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim 36:381-428.
17. Bailey, J., T. Capaldo, K. Conlee, M. Thew, and J. Pippin. 2008. Experimental use of nonhuman primates is not a simple problem. Nat Med 14:1011-2; discussion 1012-3.
18. Bakari, M., S. Aboud, C. Nilsson, J. Francis, D. Buma, C. Moshiro, E. A. Aris, E. F. Lyamuya, M. Janabi, K. Godoy-Ramirez, A. Joachim, V. R. Polonis, A. Brave, P. Earl, M. Robb, M.
Marovich, B. Wahren, K. Pallangyo, G. Biberfeld, F. Mhalu, and E. Sandstrom. 2011. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine.
19. Barnett, S. W., S. Rajasekar, H. Legg, B. Doe, D. H. Fuller, J. R. Haynes, C. M. Walker, and K.
S. Steimer. 1997. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15:869-73.
20. Barouch, D. H. 2010. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5:386-90.
21. Barouch, D. H., K. L. O'Brien, N. L. Simmons, S. L. King, P. Abbink, L. F. Maxfield, Y. H. Sun, A. La Porte, A. M. Riggs, D. M. Lynch, S. L. Clark, K. Backus, J. R. Perry, M. S. Seaman, A.
Carville, K. G. Mansfield, J. J. Szinger, W. Fischer, M. Muldoon, and B. Korber. 2010. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16:319-23.
22. Barre-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C.
Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier.
1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-71.
23. Baum, S. E., J. T. Morris, R. V. Gibbons, and R. Cooper. 1999. Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Mil Med 164:609-12.
24. Benson, J., C. Chougnet, M. Robert-Guroff, D. Montefiori, P. Markham, G. Shearer, R. C.
Gallo, M. Cranage, E. Paoletti, K. Limbach, D. Venzon, J. Tartaglia, and G. Franchini. 1998.
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol 72:4170-82.
25. Berges, B. K., W. H. Wheat, B. E. Palmer, E. Connick, and R. Akkina. 2006. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model.
Retrovirology 3:76.
26. Bergman, P. J., M. A. Camps-Palau, J. A. McKnight, N. F. Leibman, D. M. Craft, C. Leung, J.
Liao, I. Riviere, M. Sadelain, A. E. Hohenhaus, P. Gregor, A. N. Houghton, M. A. Perales, and J. D. Wolchok. 2006. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24:4582-5.
27. Bianchi, E., M. Finotto, P. Ingallinella, R. Hrin, A. V. Carella, X. S. Hou, W. A. Schleif, M. D.
Miller, R. Geleziunas, and A. Pessi. 2005. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A 102:12903-8.
28. Bins, A. D., A. Jorritsma, M. C. Wolkers, C. F. Hung, T. C. Wu, T. N. Schumacher, and J. B.
Haanen. 2005. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 11:899-904.
29. Blanchard, T. J., A. Alcami, P. Andrea, and G. L. Smith. 1998. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:
implications for use as a human vaccine. J Gen Virol 79 ( Pt 5):1159-67.
30. Blanco, R., L. Carrasco, and I. Ventoso. 2003. Cell killing by HIV-1 protease. J Biol Chem 278:1086-93.
42
31. Blazevic, V., A. Mannik, M. Malm, R. Sikut, M. Valtavaara, U. Toots, M. Ustav, and K. Krohn.
2006. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine. AIDS Res Hum Retroviruses 22:667-77.
32. Boberg, A., A. Brave, S. Johansson, B. Wahren, J. Hinkula, and E. Rollman. 2008. Murine models for HIV vaccination and challenge. Expert Rev Vaccines 7:117-30.
33. Boberg, A., S. Dominici, A. Brave, K. Hallermalm, J. Hinkula, M. Magnani, and B. Wahren.
2007. Immunization with HIV protease peptides linked to syngeneic erythrocytes. Infect Agent Cancer 2:9.
34. Boberg, A., S. Gaunitz, A. Brave, B. Wahren, and N. Carlin. 2008. Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin. Vaccine 26:5079-82.
35. Boberg, A., D. Sjostrand, E. Rollman, J. Hinkula, B. Zuber, and B. Wahren. 2006.
Immunological cross-reactivity against a drug mutated HIV-1 protease epitope after DNA multi-CTL epitope construct immunization. Vaccine 24:4527-30.
36. Boyer, J. D., T. M. Robinson, M. A. Kutzler, G. Vansant, D. A. Hokey, S. Kumar, R. Parkinson, L. Wu, M. K. Sidhu, G. N. Pavlakis, B. K. Felber, C. Brown, P. Silvera, M. G. Lewis, J.
Monforte, T. A. Waldmann, J. Eldridge, and D. B. Weiner. 2007. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A 104:18648-53.
37. Boyle, M. J., M. Connors, M. E. Flanigan, S. P. Geiger, H. Ford, Jr., M. Baseler, J.
Adelsberger, R. T. Davey, Jr., and H. C. Lane. 1995. The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy. J Immunol 154:6612-23.
38. Brady, H. J., D. J. Pennington, and E. A. Dzierzak. 1994. Transgenic mice as models of human immunodeficiency virus expression and related cellular effects. J Gen Virol 75 ( Pt 10):2549-58.
39. Braginskaia, V. P., A. F. Sokolova, and G. F. Papko. 1968. [Effectiveness of specific smallpox gamma globulin therapy in postvaccinal complications]. Vopr Okhr Materin Det 13:60-3.
40. Brave, A., A. Boberg, L. Gudmundsdotter, E. Rollman, K. Hallermalm, K. Ljungberg, P.
Blomberg, R. Stout, S. Paulie, E. Sandstrom, G. Biberfeld, P. Earl, B. Moss, J. H. Cox, and B.
Wahren. 2007. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther 15:1724-33.
41. Brave, A., L. Gudmundsdotter, E. Sandstrom, B. K. Haller, D. Hallengard, A. K. Maltais, A. D.
King, R. R. Stout, P. Blomberg, U. Hoglund, B. Hejdeman, G. Biberfeld, and B. Wahren.
2010. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine 28:8203-9.
42. Brave, A., D. Hallengard, L. Gudmundsdotter, R. Stout, R. Walters, B. Wahren, and K.
Hallermalm. 2009. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen. Vaccine 27:3692-6.
43. Brave, A., K. Ljungberg, A. Boberg, E. Rollman, G. Engstrom, J. Hinkula, and B. Wahren.
2006. Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine 24:4524-6.
44. Brave, A., K. Ljungberg, A. Boberg, E. Rollman, M. Isaguliants, B. Lundgren, P. Blomberg, J.
Hinkula, and B. Wahren. 2005. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 12:1197-205.
45. Brave, A., K. Ljungberg, B. Wahren, and M. A. Liu. 2007. Vaccine delivery methods using viral vectors. Mol Pharm 4:18-32.
43
46. Brito, L. A., M. Chan, B. Baudner, S. Gallorini, G. Santos, D. T. O'Hagan, and M. Singh. 2011.
An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 29:6262-8.
47. Browning, J., J. W. Horner, M. Pettoello-Mantovani, C. Raker, S. Yurasov, R. A. DePinho, and H. Goldstein. 1997. Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci U S A 94:14637-41.
48. Buchan, S., E. Gronevik, I. Mathiesen, C. A. King, F. K. Stevenson, and J. Rice. 2005.
Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J Immunol 174:6292-8.
49. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J.
R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A.
Chodakewitz, L. Corey, and M. N. Robertson. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-93.
50. Burton, D. R., R. L. Stanfield, and I. A. Wilson. 2005. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 102:14943-8.
51. Cafaro, A., A. Caputo, C. Fracasso, M. T. Maggiorella, D. Goletti, S. Baroncelli, M. Pace, L.
Sernicola, M. L. Koanga-Mogtomo, M. Betti, A. Borsetti, R. Belli, L. Akerblom, F. Corrias, S.
Butto, J. Heeney, P. Verani, F. Titti, and B. Ensoli. 1999. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 5:643-50.
52. Calarota, S., G. Bratt, S. Nordlund, J. Hinkula, A. C. Leandersson, E. Sandstrom, and B.
Wahren. 1998. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351:1320-5.
53. Carpenter, S., and L. A. O'Neill. 2007. How important are Toll-like receptors for antimicrobial responses? Cell Microbiol 9:1891-901.
54. Clavel, F., D. Guetard, F. Brun-Vezinet, S. Chamaret, M. A. Rey, M. O. Santos-Ferreira, A. G.
Laurent, C. Dauguet, C. Katlama, C. Rouzioux, and et al. 1986. Isolation of a new human retrovirus from West African patients with AIDS. Science 233:343-6.
55. Coffin, J., A. Haase, J. A. Levy, L. Montagnier, S. Oroszlan, N. Teich, H. Temin, K. Toyoshima, H. Varmus, P. Vogt, and et al. 1986. Human immunodeficiency viruses. Science 232:697.
56. Collier, B., D. Oberg, X. Zhao, and S. Schwartz. 2002. Specific inactivation of inhibitory sequences in the 5' end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J Virol 76:2739-52.
57. Collins, K. L., B. K. Chen, S. A. Kalams, B. D. Walker, and D. Baltimore. 1998. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391:397-401.
58. Costa, S. M., A. S. Azevedo, M. V. Paes, F. S. Sarges, M. S. Freire, and A. M. Alves. 2007.
DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. Virology 358:413-23.
59. Cranage, M. P., C. A. Fraser, Z. Stevens, J. Huting, M. Chang, S. A. Jeffs, M. S. Seaman, A.
Cope, T. Cole, and R. J. Shattock. 2010. Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol 3:57-68.
60. Cristillo, A. D., S. Wang, M. S. Caskey, T. Unangst, L. Hocker, L. He, L. Hudacik, S. Whitney, T.
Keen, T. H. Chou, S. Shen, S. Joshi, V. S. Kalyanaraman, B. Nair, P. Markham, S. Lu, and R.
Pal. 2006. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 346:151-68.
61. Crooks, E. T., P. L. Moore, M. Franti, C. S. Cayanan, P. Zhu, P. Jiang, R. P. de Vries, C. Wiley, I. Zharkikh, N. Schulke, K. H. Roux, D. C. Montefiori, D. R. Burton, and J. M. Binley. 2007. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366:245-62.
44
62. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-41.
63. Davidson, A. H., J. L. Traub-Dargatz, R. M. Rodeheaver, E. N. Ostlund, D. D. Pedersen, R. G.
Moorhead, J. B. Stricklin, R. D. Dewell, S. D. Roach, R. E. Long, S. J. Albers, R. J. Callan, and M. D. Salman. 2005. Immunologic responses to West Nile virus in vaccinated and clinically affected horses. J Am Vet Med Assoc 226:240-5.
64. Davis, H. L., C. L. Millan, and S. C. Watkins. 1997. Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA.
Gene Ther 4:181-8.
65. De Milito, A., B. Hejdeman, J. Albert, S. Aleman, A. Sonnerborg, M. Zazzi, and F. Chiodi.
2000. High plasma levels of soluble fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy. AIDS Res Hum Retroviruses 16:1379-84.
66. Deeks, S. G., and B. D. Walker. 2007. Human immunodeficiency virus controllers:
mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-16.
67. Delaloye, J., T. Roger, Q. G. Steiner-Tardivel, D. Le Roy, M. Knaup Reymond, S. Akira, V.
Petrilli, C. E. Gomez, B. Perdiguero, J. Tschopp, G. Pantaleo, M. Esteban, and T. Calandra.
2009. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5:e1000480.
68. Doan, L. X., M. Li, C. Chen, and Q. Yao. 2005. Virus-like particles as HIV-1 vaccines. Rev Med Virol 15:75-88.
69. Douek, D. 2007. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 15:114-7.
70. Downing, M., T. H. Riess, K. Vernon, N. Mulia, M. Hollinquest, C. McKnight, D. C. Jarlais, and B. R. Edlin. 2005. What's community got to do with it? Implementation models of syringe exchange programs. AIDS Educ Prev 17:68-78.
71. Dupuis, M., K. Denis-Mize, A. LaBarbara, W. Peters, I. F. Charo, D. M. McDonald, and G. Ott.
2001. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis.
Eur J Immunol 31:2910-8.
72. Dupuis, M., T. J. Murphy, D. Higgins, M. Ugozzoli, G. van Nest, G. Ott, and D. M. McDonald.
1998. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 186:18-27.
73. Dvorak, A. M., and H. F. Dvorak. 1974. Structure of Freund's complete and incomplete adjuvants. Relation of adjuvanticity to structure. Immunology 27:99-114.
74. El Safadi, Y., V. Vivet-Boudou, and R. Marquet. 2007. HIV-1 reverse transcriptase inhibitors.
Appl Microbiol Biotechnol 75:723-37.
75. Emerman, M., and M. H. Malim. 1998. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280:1880-4.
76. Evering, T. H., and M. Markowitz. 2008. Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs 17:413-22.
77. Ferrantelli, F., R. A. Rasmussen, K. A. Buckley, P. L. Li, T. Wang, D. C. Montefiori, H.
Katinger, G. Stiegler, D. C. Anderson, H. M. McClure, and R. M. Ruprecht. 2004. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 189:2167-73.
78. Fischer, W., S. Perkins, J. Theiler, T. Bhattacharya, K. Yusim, R. Funkhouser, C. Kuiken, B.
Haynes, N. L. Letvin, B. D. Walker, B. H. Hahn, and B. T. Korber. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13:100-6.
79. Fu, T. M., L. Guan, A. Friedman, T. L. Schofield, J. B. Ulmer, M. A. Liu, and J. J. Donnelly.
1999. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol 162:4163-70.
45
80. Fu, T. M., J. B. Ulmer, M. J. Caulfield, R. R. Deck, A. Friedman, S. Wang, X. Liu, J. J. Donnelly, and M. A. Liu. 1997. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 3:362-71.
81. Fuller, D. H., P. A. Rajakumar, L. A. Wilson, A. M. Trichel, J. T. Fuller, T. Shipley, M. S. Wu, K.
Weis, C. R. Rinaldo, J. R. Haynes, and M. Murphey-Corb. 2002. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 76:3309-17.
82. Fynan, E. F., R. G. Webster, D. H. Fuller, J. R. Haynes, J. C. Santoro, and H. L. Robinson.
1993. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 90:11478-82.
83. Gallo, R. C., S. Z. Salahuddin, M. Popovic, G. M. Shearer, M. Kaplan, B. F. Haynes, T. J.
Palker, R. Redfield, J. Oleske, B. Safai, and et al. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500-3.
84. Gao, F., E. Bailes, D. L. Robertson, Y. Chen, C. M. Rodenburg, S. F. Michael, L. B. Cummins, L.
O. Arthur, M. Peeters, G. M. Shaw, P. M. Sharp, and B. H. Hahn. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436-41.
85. Gardiner, D. F., Y. Huang, S. Basu, L. Leung, Y. Song, Z. Chen, and D. D. Ho. 2006. Multiple-site DNA vaccination enhances immune responses in mice. Vaccine 24:287-92.
86. Gardner, M. B. 1990. SIV infection of macaques: a model for AIDS vaccine development. Dev Biol Stand 72:259-66.
87. Garver, K. A., S. E. LaPatra, and G. Kurath. 2005. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O.
nerka salmon. Dis Aquat Organ 64:13-22.
88. Garzino-Demo, A., A. L. DeVico, F. Cocchi, and R. C. Gallo. 1998. Beta-chemokines and protection from HIV type 1 disease. AIDS Res Hum Retroviruses 14 Suppl 2:S177-84.
89. Gasteiger, G., W. Kastenmuller, R. Ljapoci, G. Sutter, and I. Drexler. 2007. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 81:11925-36.
90. Girard, M. P., S. K. Osmanov, and M. P. Kieny. 2006. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24:4062-81.
91. Goodenow, M., T. Huet, W. Saurin, S. Kwok, J. Sninsky, and S. Wain-Hobson. 1989. HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr 2:344-52.
92. Gothelf, A., F. Mahmood, F. Dagnaes-Hansen, and J. Gehl. 2011. Efficacy of transgene expression in porcine skin as a function of electrode choice. Bioelectrochemistry.
93. Gray, R. H., M. J. Wawer, R. Brookmeyer, N. K. Sewankambo, D. Serwadda, F. Wabwire-Mangen, T. Lutalo, X. Li, T. vanCott, and T. C. Quinn. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.
Lancet 357:1149-53.
94. Greenland, J. R., R. Geiben, S. Ghosh, W. A. Pastor, and N. L. Letvin. 2007. Plasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis. J Immunol 178:5652-8.
95. Greenland, J. R., and N. L. Letvin. 2007. Chemical adjuvants for plasmid DNA vaccines.
Vaccine 25:3731-41.
96. Grosjean, H., and W. Fiers. 1982. Preferential codon usage in prokaryotic genes: the optimal codon-anticodon interaction energy and the selective codon usage in efficiently expressed genes. Gene 18:199-209.
97. Guadalupe, M., E. Reay, S. Sankaran, T. Prindiville, J. Flamm, A. McNeil, and S. Dandekar.
2003. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human
46
immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77:11708-17.
98. Gudmundsdotter, L., C. Nilsson, A. Brave, B. Hejdeman, P. Earl, B. Moss, M. Robb, J. Cox, N.
Michael, M. Marovich, G. Biberfeld, E. Sandstrom, and B. Wahren. 2009. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 27:4468-74.
99. Gudmundsdotter, L., A. Sjodin, A. C. Bostrom, B. Hejdeman, R. Theve-Palm, A. Alaeus, K.
Lidman, and B. Wahren. 2006. Therapeutic immunization for HIV. Springer Semin Immunopathol 28:221-30.
100. Hahn, B. H., G. M. Shaw, S. K. Arya, M. Popovic, R. C. Gallo, and F. Wong-Staal. 1984.
Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature 312:166-9.
101. Haigwood, N. L., C. C. Pierce, M. N. Robertson, A. J. Watson, D. C. Montefiori, M. Rabin, J.
B. Lynch, L. Kuller, J. Thompson, W. R. Morton, R. E. Benveniste, S. L. Hu, P. Greenberg, and S. P. Mossman. 1999. Protection from pathogenic SIV challenge using multigenic DNA vaccines. Immunol Lett 66:183-8.
102. Hallengard, D., B. K. Haller, A. K. Maltais, E. Gelius, K. Nihlmark, B. Wahren, and A. Brave.
2011. Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation. Clin Vaccine Immunol.
103. Hallengard, D., B. K. Haller, S. Petersson, A. Boberg, A. K. Maltais, M. Isaguliants, B.
Wahren, and A. Brave. 2011. Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 29:839-48.
104. Han, F., L. Lin, S. C. Warby, J. Faraco, J. Li, S. X. Dong, P. An, L. Zhao, L. H. Wang, Q. Y. Li, H.
Yan, Z. C. Gao, Y. Yuan, K. P. Strohl, and E. Mignot. 2011. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china. Ann Neurol 70:410-7.
105. Harari, A., P. A. Bart, W. Stohr, G. Tapia, M. Garcia, E. Medjitna-Rais, S. Burnet, C. Cellerai, O. Erlwein, T. Barber, C. Moog, P. Liljestrom, R. Wagner, H. Wolf, J. P. Kraehenbuhl, M.
Esteban, J. Heeney, M. J. Frachette, J. Tartaglia, S. McCormack, A. Babiker, J. Weber, and G.
Pantaleo. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205:63-77.
106. Heeney, J. L., A. G. Dalgleish, and R. A. Weiss. 2006. Origins of HIV and the evolution of resistance to AIDS. Science 313:462-6.
107. Hessell, A. J., L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M.
Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, P. A. Marx, and D. R. Burton. 2007. Fc receptor but not complement binding is important in antibody protection against HIV.
Nature 449:101-4.
108. Hessell, A. J., P. Poignard, M. Hunter, L. Hangartner, D. M. Tehrani, W. K. Bleeker, P. W.
Parren, P. A. Marx, and D. R. Burton. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15:951-4.
109. Hirao, L. A., R. Draghia-Akli, J. T. Prigge, M. Yang, A. Satishchandran, L. Wu, E. Hammarlund, A. S. Khan, T. Babas, L. Rhodes, P. Silvera, M. Slifka, N. Y. Sardesai, and D. B. Weiner. 2011.
Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 203:95-102.
110. Hirao, L. A., L. Wu, A. S. Khan, A. Satishchandran, R. Draghia-Akli, and D. B. Weiner. 2008.
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26:440-8.
111. Hirao, L. A., L. Wu, A. Satishchandran, A. S. Khan, R. Draghia-Akli, A. C. Finnefrock, A. J.
Bett, M. R. Betts, D. R. Casimiro, N. Y. Sardesai, J. J. Kim, J. W. Shiver, and D. B. Weiner.
2010. Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther 18:1568-76.
47
112. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995.
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-6.
113. Hoebe, K., E. Janssen, and B. Beutler. 2004. The interface between innate and adaptive immunity. Nat Immunol 5:971-4.
114. Hojman, P., H. Gissel, and J. Gehl. 2007. Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation. Gene Ther 14:950-9.
115. Hutnick, N. A., D. G. Carnathan, S. A. Dubey, G. Makedonas, K. S. Cox, L. Kierstead, S. J.
Ratcliffe, M. N. Robertson, D. R. Casimiro, H. C. Ertl, and M. R. Betts. 2009. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+
T cells. Nat Med 15:876-8.
116. Iqbal, S. M., T. B. Ball, J. Kimani, P. Kiama, P. Thottingal, J. E. Embree, K. R. Fowke, and F. A.
Plummer. 2005. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 192:728-38.
117. Isaguliants, M. G., N. N. Petrakova, B. Zuber, K. Pokrovskaya, R. Gizatullin, D. A. Kostyuk, A.
Kjerrstrom, G. Winberg, S. N. Kochetkov, J. Hinkula, and B. Wahren. 2000. DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge. Intervirology 43:288-93.
118. Ishii, K. J., T. Kawagoe, S. Koyama, K. Matsui, H. Kumar, T. Kawai, S. Uematsu, O. Takeuchi, F. Takeshita, C. Coban, and S. Akira. 2008. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451:725-9.
119. Jansen, C. A., S. Kostense, K. Vandenberghe, N. M. Nanlohy, I. M. De Cuyper, E. Piriou, E. H.
Manting, F. Miedema, and D. van Baarle. 2005. High responsiveness of HLA-B57-restricted Gag-specific CD8+ T cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection. Eur J Immunol 35:150-8.
120. Jetzt, A. E., H. Yu, G. J. Klarmann, Y. Ron, B. D. Preston, and J. P. Dougherty. 2000. High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 74:1234-40.
121. Jin, X., D. E. Bauer, S. E. Tuttleton, S. Lewin, A. Gettie, J. Blanchard, C. E. Irwin, J. T. Safrit, J.
Mittler, L. Weinberger, L. G. Kostrikis, L. Zhang, A. S. Perelson, and D. D. Ho. 1999. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189:991-8.
122. Johansson, S., M. Ek, B. Wahren, R. Stout, M. Liu, and K. Hallermalm. 2007. Intracellular targeting of CEA results in Th1-type antibody responses following intradermal genetic vaccination by a needle-free jet injection device. ScientificWorldJournal 7:987-99.
123. Jung, A. C., and D. S. Paauw. 1998. Diagnosing HIV-related disease: using the CD4 count as a guide. J Gen Intern Med 13:131-6.
124. Kamp, W., M. B. Berk, C. J. Visser, and H. S. Nottet. 2000. Mechanisms of HIV-1 to escape from the host immune surveillance. Eur J Clin Invest 30:740-6.
125. Kanitakis, J. 2002. Anatomy, histology and immunohistochemistry of normal human skin. Eur J Dermatol 12:390-9; quiz 400-1.
126. Keele, B. F., F. Van Heuverswyn, Y. Li, E. Bailes, J. Takehisa, M. L. Santiago, F. Bibollet-Ruche, Y. Chen, L. V. Wain, F. Liegeois, S. Loul, E. M. Ngole, Y. Bienvenue, E. Delaporte, J. F.
Brookfield, P. M. Sharp, G. M. Shaw, M. Peeters, and B. H. Hahn. 2006. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313:523-6.
127. Kidorf, M., and V. L. King. 2008. Expanding the public health benefits of syringe exchange programs. Can J Psychiatry 53:487-95.
128. Kiepiela, P., K. Ngumbela, C. Thobakgale, D. Ramduth, I. Honeyborne, E. Moodley, S.
Reddy, C. de Pierres, Z. Mncube, N. Mkhwanazi, K. Bishop, M. van der Stok, K. Nair, N.
Khan, H. Crawford, R. Payne, A. Leslie, J. Prado, A. Prendergast, J. Frater, N. McCarthy, C.
Brander, G. H. Learn, D. Nickle, C. Rousseau, H. Coovadia, J. I. Mullins, D. Heckerman, B. D.